Literature DB >> 34364043

Interleukin-17A (IL-17A): A silent amplifier of COVID-19.

Francesco Maione1, Gian Marco Casillo1, Federica Raucci1, Cristian Salvatore2, Giovanna Ambrosini2, Luisa Costa3, Raffaele Scarpa3, Francesco Caso4, Mariarosaria Bucci5.   

Abstract

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  COVID-19; Cytokine storm; IL-17A; Immunotherapy; Th17

Year:  2021        PMID： 34364043     DOI： 10.1016/j.biopha.2021.111980

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  6 in total

1.  Integration and Reanalysis of Four RNA-Seq Datasets Including BALF, Nasopharyngeal Swabs, Lung Biopsy, and Mouse Models Reveals Common Immune Features of COVID-19.

Authors:  Rudi Alberts; Sze Chun Chan; Qian-Fang Meng; Shan He; Lang Rao; Xindong Liu; Yongliang Zhang
Journal:  Immune Netw       Date:  2022-05-19       Impact factor: 5.851

Review 2.  Maternal and Adult Interleukin-17A Exposure and Autism Spectrum Disorder.

Authors:  Masashi Fujitani; Hisao Miyajima; Yoshinori Otani; Xinlang Liu
Journal:  Front Psychiatry       Date:  2022-02-08       Impact factor: 4.157

3.  Up-regulated serum levels of interleukin (IL)-17A and IL-22 in Egyptian pediatric patients with COVID-19 and MIS-C: Relation to the disease outcome.

Authors:  Gehan Ahmed Mostafa; Hanan Mohamed Ibrahim; Abeer Al Sayed Shehab; Sondos Mohamed Magdy; Nada AboAbdoun Soliman; Dalia Fathy El-Sherif
Journal:  Cytokine       Date:  2022-04-04       Impact factor: 3.926

Review 4.  Individual genetic variability mainly of Proinflammatory cytokines, cytokine receptors, and toll-like receptors dictates pathophysiology of COVID-19 disease.

Authors:  Mohammad Kazem Vakil; Yaser Mansoori; Ghaidaa Raheem Lateef Al-Awsi; Ali Hosseinipour; Samaneh Ahsant; Sedigheh Ahmadi; Mohammad Ekrahi; Zahra Montaseri; Babak Pezeshki; Poopak Mohaghegh; Mojtaba Sohrabpour; Maryam Bahmanyar; Abdolreza Daraei; Tahereh Dadkhah Jouybari; Alireza Tavassoli; Abdolmajid Ghasemian
Journal:  J Med Virol       Date:  2022-05-31       Impact factor: 20.693

Review 5.  Possible Role of Matrix Metalloproteinases and TGF-β in COVID-19 Severity and Sequelae.

Authors:  Gustavo Ramírez-Martínez; Luis Armando Jiménez-Álvarez; Alfredo Cruz-Lagunas; Sergio Ignacio-Cortés; Itzel Alejandra Gómez-García; Tatiana Sofia Rodríguez-Reyna; José Alberto Choreño-Parra; Joaquín Zúñiga
Journal:  J Interferon Cytokine Res       Date:  2022-05-31       Impact factor: 3.657

6.  Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals.

Authors:  Nathella Pavan Kumar; Kadar Moideen; Arul Nancy; Nandhini Selvaraj; Rachel Mariam Renji; Saravanan Munisankar; Jeromie Wesley Vivian Thangaraj; Santhosh Kumar Muthusamy; C P Girish Kumar; Tarun Bhatnagar; Manickam Ponnaiah; Sabarinathan Ramasamy; Saravanakumar Velusamy; Manoj Vasant Murhekar; Subash Babu
Journal:  Viruses       Date:  2022-03-02       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.